Innate Pharma SA Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: May 23, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | May 23, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
Innate Pharma SA filed a routine 6-K, no major news.
AI Summary
On May 23, 2024, Innate Pharma SA filed a Form 6-K. This report is for a foreign private issuer and does not contain specific financial figures or operational updates beyond confirming its filing status. The company is incorporated in France and its fiscal year ends on December 31st.
Why It Matters
This filing indicates Innate Pharma SA is meeting its reporting obligations as a foreign private issuer, which is standard procedure for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This is a standard procedural filing for a foreign private issuer and does not contain new material information.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- May 23, 2024 (date) — Filing Date
- 001-39084 (other) — Commission File Number
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
Who is the registrant filing this report?
The registrant is Innate Pharma S.A.
What is the date of this report?
The date of the report is May 23, 2024.
Does Innate Pharma SA file annual reports under Form 20-F?
Yes, Innate Pharma SA indicates it files annual reports under Form 20-F.
What is the principal executive office address for Innate Pharma SA?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-05-23 16:00:44
Filing Documents
- a6kiphmay2320241.htm (6-K) — 10KB
- exhibit991-240523.htm (EX-99.1) — 12KB
- 0001598599-24-000039.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date May 23, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer